Completed PHASE2 INTERVENTIONAL 2-arm NCT00613093

Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma

Phase II Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Temodar-Resistant Malignant Glioma

Sponsor: Duke University

Conditions Anaplastic Glioma Glioblastoma Multiforme

Interventions Temodar and O6-Benzylguanine (BG)

Updated 6 times since 2017 Last updated: Jul 8, 2014 Started: Oct 31, 2002 Primary completion: Mar 31, 2006 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Anaplastic Glioma and Glioblastoma Multiforme, this trial is completed. The trial is conducted by Duke University and has accumulated 6 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Duke University
Keryx / AOI Pharmaceuticals, Inc.
National Institutes of Health (NIH)

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States